Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 month ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...

Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...

Orfoglipron was associated with improved glycemic control and weight reduction among patients with early-stage type 2 diabetes.

Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless ...